NCT01944618 (forREAL) is a clinical trial of Forxiga in Type 2 Diabetes, sponsored by AstraZeneca.

Who is sponsoring NCT01944618?

NCT01944618 is sponsored by AstraZeneca.

What drugs are being tested in NCT01944618?

Interventions in NCT01944618: Forxiga.

What condition does NCT01944618 study?

NCT01944618 studies Type 2 Diabetes.

Is NCT01944618 still recruiting?

NCT01944618 is currently terminated. Last updated 12 September 2016.

Last reviewed 2016-09-12 · How we verify

NCT01944618: forREAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

forREAL: FORXIGA (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) PRESCRIPTION EVENT MONITORING PROGRAM

Terminated Last updated 12 September 2016

What this trial tests

trial testing Forxiga in Type 2 Diabetes in 5,000 participants. Terminated before completion.

Timeline

1 October 2013

Primary endpoint
1 October 2015

1 October 2015

Quick facts

Lead sponsor	AstraZeneca
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	1 October 2013
Primary completion	1 October 2015
Estimated completion	1 October 2015
Sites	1 location across Australia

Drugs / interventions tested

Forxiga — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 75, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence rates of adverse events, specifically genital infections, urinary tract infections, increased haematocrit, renal impairment, hepatic impairment, bone fractures and cancers, in particular breast, bladder, and prostate cancers
Time frame: Up to 6 months
Assessed in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice
Any early adverse effects as a result of drug interactions in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice
Time frame: Up to 6 months
Incidence rates of spontaneously reported hypoglycaemia in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice
Time frame: Up to 6 months

Sponsor's own description

The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Forxiga

Trials testing the same drug.

NCT05743907 — Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients wi · Phase 4 · completed
NCT04473417 — Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects · Phase 1 · completed
NCT04193566 — Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes · Phase 4 · completed
NCT03407196 — Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01944618 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 12 September 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01944618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing